Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.
Our high-tech, dedicated method is applied to construct targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
Q9Y4I1
UPID:
MYO5A_HUMAN
Alternative names:
Dilute myosin heavy chain, non-muscle; Myosin heavy chain 12; Myosin-12; Myoxin
Alternative UPACC:
Q9Y4I1; A8MZC5; O60653; Q07902; Q16249; Q9UE30; Q9UE31
Background:
Unconventional myosin-Va, known by alternative names such as Dilute myosin heavy chain, non-muscle, and Myosin-12, plays a pivotal role in cellular processes. It acts as a processive actin-based motor, facilitating large steps that match the 36-nm pseudo-repeat of the actin filament. This protein is crucial for melanosome transport, vesicle movement to the plasma membrane, and possibly dendrite formation.
Therapeutic significance:
The protein's involvement in Griscelli syndrome 1, characterized by pigmentary dilution, developmental delay, and intellectual disability, underscores its therapeutic significance. Understanding the role of Unconventional myosin-Va could open doors to potential therapeutic strategies for this rare autosomal recessive disorder.